Heng M K, Zimmer I
Am Heart J. 1985 Jun;109(6):1273-80. doi: 10.1016/0002-8703(85)90351-5.
The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy. The patients received 2 weeks each of placebo, 50, 100, and 200 mg of oral atenolol. Efficacy was determined by weekly 24-hour Holter monitors. In 20 patients who completed the protocol, the frequency of total ventricular ectopic beats, ectopic couplets, and ventricular tachycardia was significantly decreased after treatment. The complexity of ventricular ectopy was also decreased as measured by the Lown grade and the proportion of hours in which multiform ectopic beats were present. A therapeutic response, defined as the minimum percentage reduction in ventricular arrhythmias to demonstrate an effect due to atenolol rather than spontaneous variation, was achieved in up to 70% of patients for total number of ectopic beats, 75% for ectopic couplets, and 73% for ventricular tachycardia beats. The results show that oral atenolol is an effective agent for the treatment for ventricular arrhythmias.
对25名有明显室性早搏的男性患者评估了阿替洛尔对室性心律失常的影响。患者分别接受了为期2周的安慰剂、50毫克、100毫克和200毫克口服阿替洛尔治疗。通过每周的24小时动态心电图监测仪来确定疗效。在完成方案的20名患者中,治疗后室性早搏总数、异位性成对搏动和室性心动过速的频率显著降低。通过洛恩分级以及存在多形性异位搏动的小时数比例来衡量,室性早搏的复杂性也有所降低。对于室性心律失常,将因阿替洛尔而非自发变化导致的效应所定义的治疗反应定义为心律失常减少的最小百分比,对于异位搏动总数,高达70%的患者实现了治疗反应,对于异位性成对搏动为75%,对于室性心动过速搏动为73%。结果表明,口服阿替洛尔是治疗室性心律失常的有效药物。